The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?

Authors

  • Larry Goldenberg Professor and Head, Department of Urologic Sciences, University of British Columbia Vancouver, BC
  • Alan So Assistant Professor, Department of Urologic Science, University of British Columbia, Vancouver, BC
  • Neil Fleshner Head, Division of Urology, University Health Network, Toronto, ON
  • Ricardo Rendon Associate Professor, Department of Urology, Dalhousie University, Halifax, NS
  • Darrel Drachenberg Assistant Professor and Director of Research, Department of Surgery, Section of Urology, University of Manitoba, Winnipeg, Manitoba
  • Mostafa Elhilali Head, Department of Surgery, McGill University, Montréal, QC

DOI:

https://doi.org/10.5489/cuaj.1114

Abstract

Normal growth and function of the prostate are contingent on the reduction
of testosterone to dihydrotestosterone (DHT) by 5-alpha reductase
(5-AR) enzymes types 1 and 2. It has been theorized that an overabundance
of DHT may be implicated in the pathogenesis of both benign prostatic hyperplasia
(BPH) and prostate cancer. Inhibitors of 5-AR such as dutasteride and
finasteride may therefore have an important role in the prevention and treatment
of BPH and prostate cancer. Dutasteride provides greater suppression of
DHT than finasteride, thereby underlying the hypothesis that inhibition of both
type 1 and type 2 would provide correspondingly greater protection than inhibition
of type 2 alone. We review the potential significance of the 5-AR
inhibitors in reducing the risk of prostate cancer according to the basic biology
of prostate disease

Downloads

Download data is not yet available.

Author Biographies

Larry Goldenberg, Professor and Head, Department of Urologic Sciences, University of British Columbia Vancouver, BC

Alan So, Assistant Professor, Department of Urologic Science, University of British Columbia, Vancouver, BC

Neil Fleshner, Head, Division of Urology, University Health Network, Toronto, ON

Ricardo Rendon, Associate Professor, Department of Urology, Dalhousie University, Halifax, NS

Darrel Drachenberg, Assistant Professor and Director of Research, Department of Surgery, Section of Urology, University of Manitoba, Winnipeg, Manitoba

Mostafa Elhilali, Head, Department of Surgery, McGill University, Montréal, QC

Downloads

How to Cite

Goldenberg, L., So, A., Fleshner, N., Rendon, R., Drachenberg, D., & Elhilali, M. (2013). The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?. Canadian Urological Association Journal, 3(3-S2), S109-S114. https://doi.org/10.5489/cuaj.1114

Issue

Vol. 3 No. 3-S2 (2009): CUAJ June-Suppl 2

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.